Cargando…

EE540 Cost-Effectiveness of Vaccines Targeting Infectious Diseases - Has COVID-19 Changed the Landscape?

Detalles Bibliográficos
Autores principales:	Pitman, R, Khurana, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747451/ http://dx.doi.org/10.1016/j.jval.2022.09.781

Ejemplares similares

EE71 Cost-Effectiveness of COVID-19 Vaccination in Colombia: A Micro-Simulation Modelling Analysis
por: Castañeda-Orjuela, C, et al.
Publicado: (2022)

EE7 Economic Evaluation of COVID-19 Vaccines: A Targeted Literature Review
por: Addae, A, et al.
Publicado: (2022)

EE564 Study on the Value Pricing of COVID-19 Vaccine in China Based on the Evidence of Cost-Effectiveness Analysis
por: Fu, Y., et al.
Publicado: (2023)

540. Does Remdesivir Impact the Clinical Outcome of Patients with COVID 19 Infection?
por: Gunasekaran, Karthik, et al.
Publicado: (2021)

EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States
por: Paret, K, et al.
Publicado: (2022)

EE19 Cost-Effectiveness Analysis of Nonpharmaceutical Interventions Combined with Inactivated Vaccination and Oral Medicine in China
por: Fu, F., et al.
Publicado: (2023)

Public policy for healthy living: How COVID-19 has changed the landscape
por: Whitsel, Laurie P., et al.
Publicado: (2023)

EE632 Winning the COVID-19 Vaccine Race: How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market
por: Folorunso, R, et al.
Publicado: (2022)

EE188 COVID-19 Vaccine Hesitancy Among Early Adaptors in Jordan
por: Muflih, S
Publicado: (2022)

EE415 Spatial Cost-Efficiency Analysis on the Separability Condition of COVID-19 Potential Determinants
por: Nepomuceno, T, et al.
Publicado: (2022)

EE238 Healthcare Costs of COVID-19 Versus Flu and Pneumonia - a Payer Perspective
por: Richards, F, et al.
Publicado: (2022)

EE527 Cost-Effectiveness and Budget Impact Analysis of Remdesivir for the Treatment of COVID-19 in Greece
por: Athanasakis, K, et al.
Publicado: (2022)

540 Trans oro Pharyngeal Spacer for Inhalers
por: Rao, Prabhakar PV, et al.
Publicado: (2012)

EE386 Cost-of-Illness Analysis of Coronavirus Disease 2019 (COVID-19) Treatment in the Philippine General Hospital
por: Castillo, RM, et al.
Publicado: (2022)

EE335 The Hospitalization Burden of COVID-19 in Patients with NSCLC: Differential Impact of Vaccination
por: Richy, F, et al.
Publicado: (2022)

EE179 Key Drivers of the Economically Justifiable Price of the COVID-19 Vaccine in England
por: Aballea, S, et al.
Publicado: (2022)

SUN-540 Inflammasome Components After Bariatric Surgery: Novel Targets for a Chronic Disease
por: Herrera-Martinez, Aura D, et al.
Publicado: (2020)

EE240 Estimating the COVID-19 Cost-of-Illness Associated with Comorbidities in a Brazilian Public Hospital
por: Oliveira, LA, et al.
Publicado: (2022)

EE468 Healthcare Resource Utilisation and Costs Associated With the Management of Hospitalised COVID-19 Patients in England
por: Patel, V, et al.
Publicado: (2022)

Measurement of the cross-section for the process $ee \to ee\gamma^{*}\gamma^{*} \to eeX$ at $\sqrt{S_{ee}}$ = 189 GeV
por: Przybycien, M B
Publicado: (2000)

Extensively Drug-Resistant Tuberculosis in the Time of COVID-19—How has the Landscape Changed for Pakistan?
por: Islam, Mahnoor
Publicado: (2020)

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study
por: Wang, Song-Yau, et al.
Publicado: (2022)

SAT-540 Bisphosphonates and Fracture Incidence in Young Adults
por: Choudhary, Manita, et al.
Publicado: (2019)

Measurement of the Cross-Section for the Process ee-ee gamma*gamma*-eeX at sqrt(s_ee) = 189 GeV
por: CERN. Geneva
Publicado: (1999)

EE99 Economic Burden of COVID-19 in Mexico
por: Frias Gasga, AE, et al.
Publicado: (2022)

EE471 Valuing the Fear of COVID-19 Contagion
por: Poudel, N, et al.
Publicado: (2022)

EE98 Health Economic Evaluation of COVID-19 Vaccines: A Systematic Literature Review
por: Li, Y., et al.
Publicado: (2023)

Target Studies for the FCC-ee Positron Source
por: Alharthi, F, et al.
Publicado: (2022)

EE211 Cost of Long COVID Following Severe Disease - a US Healthcare Database Analysis
por: Patterson, B, et al.
Publicado: (2022)

EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
por: Piccolo, F, et al.
Publicado: (2022)

CERN: First results at 540 GeV total energy
Publicado: (1982)

CERN: More 540 GeV proton-antiproton results
Publicado: (1982)

POS-540 COVID-19 IN ESRD PATIENTS WITH RENAL REPLACEMENT THERAPIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Nopsopon, T., et al.
Publicado: (2021)

Measurement of the cross-section for the process ee --> ee gamma[sup *] gamma[sup *] --> eeX at sqrt(s[sub ee]) = 189--202 GeV
por: Przybycien, M B
Publicado: (2001)

EE329 The Value-Based Price for a Bivalent COVID-19 Booster Vaccine in the United Kingdom
por: Kohli, M., et al.
Publicado: (2023)

FCC-ee
por: Janot, Patrick
Publicado: (2018)

EE422 Healthcare Costs Associated with Severe VS Moderate and Mild COVID-19 - a US Payer Perspective
por: Holy, C, et al.
Publicado: (2022)

EE467 Recovid Study. Cost-Effectivness Analysis of Using Nutridrink 200 ML in the Treatment of COVID-19 in the Hospital
por: Frolov, M
Publicado: (2022)

Nello scontro protone-antiprotone 540 miliardi di elettron-volts
por: Zichichi, A
Publicado: (1981)

Teilchenerzeugung in Proton-Antiproton-Reaktionen bei 540 GeV Schwerpunktsenergie
por: Müller, Thomas
Publicado: (1983)

Cannot write session to /tmp/vufind_sessions/sess_b4b2mu6hspbekklihegihta2pt